|
Where and when was Kendle founded?
Dr. Candace Kendle and Chris Bergen founded Kendle in 1981 in Cincinnati, Ohio, USA.
When did Kendle become a public company?
Kendle became a public company in August 1997.
Who are Kendle's Executive Officers?
- Candace Kendle, PharmD – Chairman and CEO
- Christopher Bergen – COO
- Simon Higginbotham – President
- Karl “Buzz” Brenkert III – Senior Vice President and CFO
- Alan Boyce – Vice President and CMO
In which countries does Kendle maintain an office?
Our global clinical development business is focused on five regions – North America, Europe, Asia/Pacific, Latin America and Africa – to meet customer needs. Kendle currently maintains 47 offices in the following locations.
North America
Cary, NC
Chicago, IL
Cincinnati, OH
Cranford, NJ
Los Angeles, CA
Morgantown, WV
Old Lyme, CT
Rockville, MD
Wilmington, NC |
Europe
Barcelona, Spain
Brussels, Belgium
Bucharest, Romania
Crowthorne, England
Edinburgh, Scotland
Ely, England
Glasgow, Scotland
Lyon, France
Madrid, Spain
Maidenhead, England
Milan, Italy
Moscow, Russia
Munich, Germany (2)
Paris, France (2)
Prague, Czech Republic (2)
Saronno, Italy
Sofia, Bulgaria
Tel-Aviv, Israel
Tranent, Scotland
Utrecht, The Netherlands (2)
Warsaw, Poland (2)
|
Asia/Pacific
Beijing, China
Melbourne, Australia
New Delhi, India
Singapore
Sydney, Australia
|
Latin America
Bogotå, Colombia
Buenos Aires, Argentina
Lima, Peru
Mexico City, Mexico (2)
Rio de Janeiro, Brazil
Santiago, Chile |
Africa
Johannesburg, South Africa |
|
In what industry does Kendle operate?
Kendle is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide.
What are Kendle’s core competencies?
As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Clinical Development – Phase I, IIA, II and III clinical research, including planning, project management, monitoring, feasibility, patient recruitment and retention
Regulatory Affairs – Regulatory consulting and submissions, validation and compliance, pharmacovigilance/safety, medical writing, clinical quality assurance
Biometrics – Clinical data management, biostatistics and scientific programming
Late Phase – Phase IIIB/IV studies; health economics; outcomes research; scientific events, education and publication services; quality of life studies; post-marketing research
How is Kendle organized?
Kendle operates its business in two reportable operating segments, Early Stage and Late Stage. The Early Stage business currently focuses on the Company's Phase I operations while Late Stage is comprised of clinical development services related to Phase II through IV clinical trials, regulatory affairs and biometrics offerings. The Company aggregates its clinical development operating unit, regulatory affairs operating unit, and biometrics operating unit into the Late Stage segment.
Where can I find Kendle news releases?
All news releases for Kendle are available under the Media section of our web site. You can request to receive an e-mail copy of all future releases by filling out the form on the “Contact Investor Relations” section of our web site.
News Releases
Do you have photographs available for editorial use?
Photographs of Kendle’s leadership team and Board of Directors appear along with their biographies in our online media kit. These can be sent to you electronically.
Leadership team biographies
Who should I contact at Kendle for more information, or to arrange an interview with a Kendle subject matter expert?
Lori Dorer
Director, Corporate Communications
441 Vine Street
Suite 1200
Cincinnati, Ohio 45202
Tel: +1 513 345 1685
Fax: +1 513 345 1634
Email:
 |
